JTE-7-31
High-affinity synthetic ligand of CB2, classed as a narcotic in France (Annex IV).
C₂₂H₂₈N₂O₃
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
Data sheet
Names
- IUPAC name
- 2-[2-(4-hydroxyphenyl)ethyl]-5-methoxy-4-(pentylamino)-3H-isoindol-1-one
- Other names
- JTE 7-31 · 7MV5OX2NX0
Identifiers
- Formula
- C₂₂H₂₈N₂O₃
- Molar mass
- 368.50 g/mol
- CAS
- 194358-72-0
- PubChem CID
- 19363402(new tab)
- InChIKey
- FMUMUYFMLZGXJR-UHFFFAOYSA-N
Class
- Family
- ECS modulator (research)
Updated on
Receptors and activity
- CB2Modulator95 out of 100
Ki 0,088 nM, splénocytes de rat (Inaba et coll., brevet US 6 017 919, 2000)
- CB1Modulator85 out of 100
Ki 11 nM, cervelet de rat (Inaba et coll., brevet US 6 017 919, 2000)
Subjective signature
- Calm
- 6 out of 100
- Relaxation of body and mind; reduced mental noise without marked drowsiness.
- Clarity
- 3 out of 100
- Sustained attention and clear thinking; functional lucidity, not euphoria.
- High
- 2 out of 100
- Euphoria and sensory intensity; altered perception of time and space.
- Appetite
- 3 out of 100
- Stimulation of hunger and of taste appreciation (the “munchies” effect).
- Sleep
- 4 out of 100
- Sedative effect: aids sleep onset and the continuity of deep sleep.
Pharmacology
JTE-7-31 is a synthetic ligand of cannabinoid receptors with an isoindolinone structure: 2-[2-(4-hydroxyphenyl)ethyl]-5-methoxy-4-(pentylamino)isoindolin-1-one. Described in patents filed by Japan Tobacco in 1996 and 1997, it is presented by US patent 6 017 919 (published in 2000) as one of the compounds of a series of selective ligands of peripheral cannabinoid receptors. That patent reports a Ki of 0.088 nM at CB2 (rat splenocytes) and 11 nM at CB1 (rat cerebellum), a ratio of 125. It also reports that, in mice, the compound reduces carrageenan-induced paw oedema, with a median effective dose of 0.012 mg/kg orally. No human study and no pharmacokinetic profile are published in the sources consulted, and the agonist or antagonist nature of the molecule is not measured there.
Key sources.
- Inaba et coll., Composés et usage pharmaceutique (brevet US 6 017 919, Japan Tobacco), 2000 (new tab)
- Arrêté du 14 octobre 2019 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants (new tab)
- ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (new tab)
- INCB, Green List 2026 (tableaux de la Convention de 1971) (new tab)
- PubChem, notice du composé JTE-7-31 (CID 19363402) (new tab)
- Wikipedia, notice JTE 7-31 (repère tertiaire) (new tab)
History
- Source
- Fully synthetic molecule, developed by Japan Tobacco in research on peripheral cannabinoid receptors. No source consulted reports it in a plant.
Origin (research tool)
No known biosynthetic pathway: a chemically synthesised molecule of the isoindolinone family.
Legal framework
- European Union
No harmonised control measure at European Union level was found in the sources consulted for this molecule: its status falls under national legislation. It is not listed in the INCB Green List 2026, which reproduces the schedules of the 1971 Convention.
- France
JTE-7-31 is named in Annex IV of the French list of narcotics, by the order of 14 October 2019 amending the order of 22 February 1990. This annex covers psychoactive substances classed in France or the European Union but not classed under the international conventions. Its use, possession and supply therefore fall under the narcotics regime.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
References
- Inaba et coll., Composés et usage pharmaceutique (brevet US 6 017 919, Japan Tobacco), 2000 (new tab)
- Arrêté du 14 octobre 2019 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants (new tab)
- ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (new tab)
- INCB, Green List 2026 (tableaux de la Convention de 1971) (new tab)
- PubChem, notice du composé JTE-7-31 (CID 19363402) (new tab)
- Wikipedia, notice JTE 7-31 (repère tertiaire) (new tab)
Structured data
- SMILES
- CCCCCNC1=C(C=CC2=C1CN(C2=O)CCC3=CC=C(C=C3)O)OC
- InChIKey
- FMUMUYFMLZGXJR-UHFFFAOYSA-N
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.